



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : CRIPPS et al. Confirmation No: 9488  
Appl. No. : 10/630,655  
Filed : July 31, 2003  
Title : PHARMACEUTICAL FORMULATION OF FLUTICASONE  
: PROPIONATE  
  
TC/A.U. : 1616  
Examiner : M Haghigatian  
  
Docket No.: CRIP3001C2/REF  
Customer No: 23364

**REQUEST FOR RECONSIDERATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Official Action of January 25, 2006, in connection with the above-identified application. The period for response to this Official Action has been extended to expire on June 25, 2006, by the filing herewith of a Petition for a Two month extension of time and payment of the required fee.

Since this is a response to a Final Rejection, a Notice of Appeal and the required fee is also submitted herewith to provide adequate time for the Examiner to fully consider this response and to proceed with the appeal should this prove necessary or to conduct an interview with the Examiner to further clarify any outstanding issues. The Examiner is invited to contact the undersigned to arrange an interview if the Examiner believes that this will be helpful to resolve any outstanding issues. .

The claims in the application have been reviewed and it is most respectfully submitted that all of the claims now present in the application are in full compliance with 35 USC 112 and are clearly patentable over the prior art of record as would be appreciated by one of ordinary skill in the art to which the invention pertains.

The outstanding rejections are prior art rejections on the basis of obviousness. Applicants most respectfully submit that the combination of references in the rejections do not render *prima facie* obvious the claimed subject matter to one of ordinary skill in